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Here we report the case of an ALK-positive NSCLC patient with pathological complete response within
6 months of treatment with crizotinib. This remission was further documented by PET-CT scans until 25
months after initial start of treatment where new brain lesions were detected on MRI. At this time, the
patient received local treatment and then alectinib with partial response of the brain metastases and
ongoing status of no systematic disease in the PET scans. This case emphasizes the relevance of brain MRI
in the follow-up of patients with ALK-translocated adenocarcinoma of the lung, the long-term response
to crizotinib and the possibility of CNS disease control with alectinib.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Presentation of the case
A 76-year old man was referred to our hospital with a newly
diagnosed adenocarcinoma of the lung. The patient was a former
smoker (less than 10 pack-years) with good performance status.
Staging with PET-CT scan showed a cT4 cN3 cM0, UICC Stage IV on
November 2011 (Fig. 1a). Biopsy of a supraclavicular lymph node
on the right side showed a poorly differentiated adenocarcinoma
without EGFR mutation.
A palliative chemotherapy with cisplatin-pemetrexed and
bevacizumab was initiated for a total of 3 cycles and at this time a
re-staging with PET-CT showed a stable disease. As during che-
motherapy the patient experienced side effects as persistent
nausea and impairment of the renal function, he refused further
chemotherapy. Molecular analysis of the tumor sample showed
the presence of an ALK-EML4 translocation by ﬂuorescence in situ
hybridization (FISH) in 95% of tumor cells. Due to further symp-
tomatic disease, treatment with crizotinib started as compassio-
nate use on March 2012. The re-staging with PET-CT scan, per-
formed after 6 weeks under medication showed a partial responseLtd. This is an open access article u
versity Hospital Zurich, Rae-
255 45 48.
(A.R. Siebenhuener),
stahel@usz.ch (R. Stahel),(Fig. 1b). After 8 months of treatment one single FDG-negative
nodule in the upper lobe of right lung (representing the primary
tumor) was detected as the only pathological ﬁnding on PET-CT.
An MRI of the brain showed no sign of metastasis. As this lung
nodule represented the only lesion with suspicion for tumor, a
wedge resection was performed (Fig. 1c). The histological analysis
showed a 1.3 mm large coarse nodule with no evidence of vital
tumor cells. These ﬁndings were interpreted as a pathological
complete response.
Crizotinib was continued with no side effects for 14 months,
until the patient decided to stop the medication and a watchful
waiting strategy was planned. At the clinical and radiological fol-
low-up no signs of tumor recurrence were noted. During re-sta-
ging, 12 months after crizotinib was ended, three small brain
metastases were detected (Fig. 2a) without any other evidence of
systemic disease. Stereotactic radiotherapy for the brain lesions
was performed. A PET-CT scan and MRI of the brain were per-
formed 3 months after radiotherapy and 16 months after crizotinib
was ended, with no evidence of systemic disease (Fig. 1d) and
partial response of the brain metastases (Fig. 2b).
During another follow-up 6 months after stereotactic radio-
therapy of the brain lesions and 19 months after crizotinib was
ended, the patient developed new neurological symptoms as
ataxia, rolling gait and slow thinking. Staging with FET–PET of the
brain and PET-CT scan at this point showed an isolated metabolic
active progression of brain metastases (Fig. 2c) and no evidence ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. a–e. PET Scans and corresponding CT scans at different time points. a: before start with crizotinib; b: 6 weeks after treatment; c: 9.5 month under treatment with
crizotinib and after wedge resection of the lung nodule; d: restaging 16 months after stop of treatment with crizotinib; e: 5 months under treatment with alectinib.
A.R. Siebenhuener et al. / Cancer Treatment Communications 4 (2015) 131–133132systemic disease. As re-irradiation of this lesion was not possible,
treatment with alectinib was started. Five months after, response
of the brain metastasis was detected (Fig. 2d) as well as no further
evidence of systemic disease (Fig. 1e). The neurological symptoms,
which could also be referred to toxicity of the radiotherapy, are to
date further improving.2. Conclusion
3–5% of adenocarcinoma of the lung carries translocations of
the ALK gene. In our patient, the most common translocation re-
sulting in an aberrant fusion of ALK with the microtubule-asso-
ciated protein-like 4 gene (EML4) was detected, which results in a
cytoplasmic chimeric protein that induces oncogenic signaling [1–
3] and represents a therapeutical target [4]. Treatment with cri-
zotinib results in a better objective response rate and longer pro-
gression-free survival compared to second line single agentFig. 2. MRI brain scans at different time points. a: MRI scan showed new brain metastas
alectinib. d: after alectinib treatment (5 months).chemotherapy [5] as well as in ﬁrst line compared to standard
chemotherapy [6,7]. However these studies report a median re-
sponse of 32 weeks, with the longest complete response in one
patient at 18 months. In our case we could detect a pathological
complete response at time of surgery already within 6 months of
treatment. This remission was further documented by PET-CT
scans until 25 months after initial start of treatment where new
brain lesions were detected on MRI.
Of interest is that, although the patient discontinued the
treatment with crizotinib, time to recurrence was 12 months,
9.5 months longer than expected. About 25% of ALKþ lung cancer
present initially with brain metastases. This region will be the
typical location of progression upon treatment with crizotinib.
Among patients without baseline brain metastases who developed
progressive disease after initiation of crizotinib, 20% were diag-
nosed with brain metastases [8].
At progression, the patient received local treatment and then
alectinib [9] with partial response of the brain metastases andis 25 month after initial start of therapy. b: after stereotactic radiotherapy. c: before
A.R. Siebenhuener et al. / Cancer Treatment Communications 4 (2015) 131–133 133ongoing status of no systematic disease in the PET scans (39
months after initial start of crizotinib). This case emphasizes the
relevance of brain MRI in the follow-up of patients with ALK-
translocated adenocarcinoma of the lung, the long-term response
to crizotinib and the possibility of CNS disease control with
alectinib.Conﬂict of interest statement
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